6343-98-2

Usage

Uses

Used in Organic Synthesis:
(5-nitropyridin-2-yl)hydrazine is used as a versatile building block for the synthesis of various organic compounds due to its functional groups, which allow for a wide range of chemical reactions and the formation of diverse molecular structures.
Used in Pharmaceutical Production:
In the pharmaceutical industry, (5-nitropyridin-2-yl)hydrazine is used as a key intermediate in the synthesis of drugs. Its unique structure and functional groups enable the development of new pharmaceuticals with potential therapeutic applications.
Used in Agrochemical Production:
(5-nitropyridin-2-yl)hydrazine is also utilized in the agrochemical industry for the synthesis of pesticides and other agrochemicals, contributing to the development of effective solutions for crop protection and management.
Used in Heterocyclic Compound Synthesis:
(5-nitropyridin-2-yl)hydrazine is used as a starting material in the synthesis of heterocyclic compounds, which are important in various fields, including pharmaceuticals, materials science, and organic chemistry.
Used in Coordination Chemistry:
(5-nitropyridin-2-yl)hydrazine is used as a ligand in coordination chemistry, where it can form complexes with metal ions, leading to the development of new materials with unique properties and potential applications in various fields.
Used in Medicinal Chemistry Research:
(5-nitropyridin-2-yl)hydrazine is being studied for its biological properties, with potential applications in medicinal chemistry. Its unique structure and functional groups make it a promising candidate for the development of new drugs and therapeutic agents.

InChI:InChI=1/C5H6N4O2/c6-8-5-2-1-4(3-7-5)9(10)11/h1-3H,6H2,(H,7,8)

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 5446-92-4 2-methoxy-5-nitropyridine 
• 31594-45-3 2-ethoxy-5-nitropyridine 

Downstream Products

• 15367-19-8 2-Benzylidenhydrazino-5-nitro-pyridin 
• 35235-73-5 6-nitro-[1,2,3,4]tetrazolo[1,5-a]pyridine 
• 31053-00-6 2-Acetylhydrazid-5-nitropyridin 
• 132499-96-8 BTNPHTS 
• 132499-94-6 NPHQTS 
• 132499-97-9 BINPHTS 
• 88713-46-6 (benzoyloxy-2 ethoxymethyl)-2 nitro-6-s-triazolo<1,5-a>pyridine 
• 76211-93-3 2-(3',5'-diphenylpyrazol-1'-yl)-5-nitropyridine 
• 78796-90-4 2-(3',4'-di-O-benzoyl-2',6'-dideoxy-L-arabino-hex-1'-enopyranosyl)-6-nitro<1,2,4>triazolo<1,5-a>pyridine 
• 78796-89-1 2-(2',3',4'-tri-O-benzoyl-6'-deoxy-α-L-manno-hexopyranosyl)-6-nitro<1,2,4>triazolo<1,5-a>pyridine 
• 76211-92-2 2-(3',5'-dimethylpyrazol-1'-yl)-5-nitropyridine 
• 110973-62-1 6-nitro-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine 
• 28058-43-7 5-Nitro-2-pyridyl-furfural-hydrazon 
• 173213-19-9 2-pyrimidinecarbaldehyde-(5-nitro-2-pyridyl)hydrazone 

Relevant academic research and scientific papers

Synthesis of Hydrazinylpyridines via Nucleophilic Aromatic Substitution and Further Transformation to Bicyclo[22.2]octenes Fused with Two N -Aminosuccinimide Moieties

Efficient and reliable synthesis of substituted hydrazinylpyridines in thick-wall ACE tubes via nucleophilic substitution of a chlorine substituent in different chloropyridines is presented. Hydrazine hydrate and alkylhydrazines were used as nucleophiles and simple alcohols and diethyl ether were the only organic solvents necessary, making the process environmentally and user friendly, potentially reaching 100% atomic efficiency. In the next step, transformations of succinic anhydride moieties fused to the bicyclo[2.2.2]octene framework into succinimide moieties via nucleophilic substitution of oxygens were conducted. As nucleophiles two of the synthesized hydrazinylpyridines (2-hydrazinyl-3-nitropyridine and 2-hydrazinyl-5-nitropyridine) and also hydrazine hydrate, phenylhydrazine, and 4-nitrophenylhydrazine were used. Reactions were again carried out in ACE tubes and only simple alcohols, diethyl ether, and acetone were needed as solvents. One of the prepared bicyclo[2.2.2]octene adducts displayed water solubility thus being a promising candidate for future studies as a novel bidentate ligand for various metal cations in aqueous solutions or acting as an unprecedented halogen bond acceptor.

Pyridine hydrazone derivative as well as preparation method and application thereof (by machine translation)

The invention relates to a pyrazine hydrazone derivative represented I, a pharmaceutically acceptable salt thereof, a pharmaceutical composition and application thereof in preparation of an influenza virus neuraminidase inhibitor. Wherein R-substituted pyridyl is selected from the group consisting of 5 - trifluoromethyl -2 - pyridyl, 3 - nitro -2 - pyridyl; Y is selected from the group consisting of: hydroxy, dihydroxyl, 3 - hydroxy -2 - C1 - C2 alkoxy, 3 - hydroxy -4 - C1 - C2 alkoxy, 3 - hydroxy -5 - C1 - C2, 3 -hydroxy -3 - C1 - C2 -6 - C1 - C2 alkoxy 4 -3 4 - hydroxy -2 - C1 - C2-4 - 5 -C1 - C2 dimethyl, Z is 4 - selected from -3: 5 - CH or N. sub. CO. (by machine translation)

PLATINUM COMPOUNDS FOR BINDING GUANINE QUADRAPLEXES

Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.

SUBSTITUTED SULFONYL HYDRAZIDES AS INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY

The present invention relates to substituted sulfonyl hydrazides that have the ability to inhibit lysine biosynthesis via the diaminopimelate pathway in certain organisms. As a result of this activity these compounds can be used in applications where inhibition of lysine biosynthesis is useful applications of this type include the use of the compound as herbicides and/or anti- bacterial agents.

Keeping it small, polar, and non-flat: diversely functionalized building blocks containing the privileged 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]- and [1,5-a]pyridine cores

Six sets of functionalized building blocks based on 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine as well as 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridine cores have been prepared. These compounds are non-flat, bicyclic heterocycles that are likely to find utility as privileged motifs for lead-like compound design. One set of building blocks, (5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-6-ylmethyl)amines, proved useful as a scaffold for developing compounds that stimulate glucagon-like peptide-1 (GLP-1) secretion and are novel anti-diabetes drug leads.

Efficient synthesis of nebularine and vidarabine via dehydrazination of (hetero)aromatics catalyzed by CuSO4 in water

A simple dehydrazination reaction has been achieved in the presence of a catalytic amount of CuSO4 for the first time. With CuSO4 (2 mol%) as a catalyst and water as a solvent, the dehydrazination products were obtained in good yields (66-95%). Moreover, the drugs nebularine and vidarabine were afforded successfully, and vidarabine could be produced on a 0.923 kg scale, which shows good potential for industrial applications.

Photo-driven optical oscillators in the kHz range based on push-pull hydroxyazopyridines

Push-pull azophenols are valuable target molecules for stable photo-driven optical oscillators. Hydroxyazopyridinium methyl iodide salts show oscillation frequencies up to 10 kHz with no signs of fatigue upon continuous work. The Royal Society of Chemistry.

Cyclic AMP-specific phosphodiesterase inhibitors

Pyrazole compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as

Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: Synthesis and antiproliferative activity

A series of N-heteroaryl hydrazones derived from aryl N-heteroaryl or bis-N-heteroaryl methanones was prepared in search for potential novel antitumor agents. The stereochemistry of these compounds was established by means of NMR spectroscopy. Antiproliferative activity was determined in a panel of human tumor cell lines (CCRF-CEM, Burkitt's lymphoma, HeLa, ZR-75- 1, HT-29, and MEXF 276L) in vitro. Generally, the new compounds were found to be more potent (IC50 = 0.011-0.436 μM) than the ribonucleotide reductase inhibitor hydroxyurea (IC50 = 140 μM). Most of the compounds exhibited the highest activity against Burkitt's lymphoma with an IC50 of 0.011-0.035 μM. [14C]Cytidine incorporation into DNA was quantitated for selected hydrazones (Z-A, E-1, Z-3, Z-4, E-5, Z-5, E-13, E-18, Z-19, Z-24, and E-26) as a measure of the inhibition of ribonucleotide reductase in Burkitt's lymphoma cells. The E-configurated compounds were found to inhibit [14C]cytidine incorporation to a greater extent (IC50 = 0.67-5.05 μM) than the Z-isomers (IC50 = 7.20 to > 10 μM). Principal component analysis of the IC50 values obtained for inhibition of cell proliferation revealed that the cell lines tested can be grouped into three main families showing different sensitivities toward the compounds in our series [(i) CCRF-CEM, Burkitt's lymphoma, and Hela; (ii) HT-29; and (iii) MEXF 276 L].

Novel potassium channel openers: Synthesis and pharmacological evaluation of new N-(substituted-3-pyridyl)-N'-alkylthioureas and related compounds

This report describes the synthesis and pharmacological evaluation of a series of novel potassium channel openers related to the pinacidil-type compounds. Thioureas, cyanoguanidines, and pyridine N-oxides were systematically evaluated for their effects on both the inhibition of spontaneous mechanical activity in rat portal vein (in vitro) and their antihypertensive activity (in vivo), and the structure-activity relationship for this series of compounds was discussed. Good correlation between in vitro and iv antihypertensive activity was observed for these compounds. Among them, cyanoguanidines bearing a conformationally rigid unit such as a norbornyl group generally possessed potent activity in both in vitro and in vivo studies. Especially, N-(6-amino-3-pyridyl)-N'-cyano-N''-(1-methyl-2- norbornyl)guanidine (23d) was identified as a more potent potassium channel opener in vitro (EC100 = 3 x 10-8 M) than pinacidil (EC100 = 10-7 M).